[276 Pages Report] The global swine respiratory diseases treatment market size is expected to reach a valuation of USD 2.0 Billion by the end of 2022, and further expand at a CAGR of 6.3% from 2022 to 2032. The market is likely to reach a valuation of USD 3.6 Billion by the end of 2032. Mycoplasma under the causative agent segment is leading the swine respiratory diseases treatment market and it held a share of about 35.2% in 2021.
Based on the severity and duration of the observable condition, swine respiratory disorders can be grouped into two main categories: those that affect a significant number of pigs and may be hazardous but only last a short while, and those that affect a large number of pigs for an extended period of time. Costs of diseases in the first category are limited rather than continuing.
Swine influenza, classical swine fever, pneumonic pseudorabies, porcine circovirus-associated illness, and pig reproductive and respiratory syndrome (PRRS) are categorized among them. Although pathogenic viruses may survive in a herd, outbreaks of overt sickness are usually self-limiting. Mycoplasma pneumonia and pleuropneumonia are the most common syndromes in the second category like rhinitis atrophic.
| Attributes | Key Statistics |
|---|---|
| Global Swine Respiratory Diseases Treatment Market Estimated Size (2022E) | USD 1,978.1 Million |
| Projected Market Valuation (2032F) | USD 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Collective Value Share: Top 5 Countries | 61.4% |
The global swine respiratory diseases treatment market held approximately 1.9% of the overall veterinary services market, which was worth ~USD 99.5 Billion in 2021. Sales of swine respiratory disease treatment services expanded at a CAGR of 6.1% from 2012 to 2021.
Demand for swine respiratory disease treatment options is on the rise due to the increasing number of foodborne and zoonotic diseases. According to the most recent annual report on food diseases issued by the European Food Safety Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC) in February 2021, foodborne infections are on the rise compared to the previous year, with pathogenic bacteria such as campylobacter spp. being the most common cause.
Around 5175 food outbreaks were documented, accounting for 49463 clinical cases, 3859 hospital admissions, and 60 deaths (+50% compared to the previous year). Salmonella, norovirus, escherichia coli, yersinia enterocolitica, cryptosporidium parvum, and campylobacter jejuni were the most common etiological agents found, while the most common causes of infection were eggs & egg products, bakery items, hog meat, processed foods, water, crustaceans, and vegetables.
Additionally, the market for swine respiratory diseases treatment is anticipated to grow in terms of research & development (R&D) spending and revenue owing to external partnerships and strategic alliances between industries and academia. For instance, in September 2022, Zoetis acquired NewMetrica, which had developed cutting-edge digital instruments in the form of standardized questionnaires that were intended to evaluate health-related quality of life (HRQL) in nonverbal species, as a strategic addition to their companion animal portfolio. Thus, owing to the aforementioned factors, the global swine respiratory diseases treatment market is expected to grow at a CAGR of 6.3% during the forecast period from 2022 to 2032.
Government Investments to Boost Access to Advanced Treatment Will Aid Growth
The market is likely to provide an opportunistic perspective owing to various initiatives by governments in emerging countries. Government bodies are investing significantly in healthcare infrastructure modernization, which is expected to bolster access to advanced healthcare services. This factor is set to fuel demand for upgraded technologies, thereby creating an appealing opportunity in the global swine respiratory diseases treatment market.
In high-income economies like the UK and the USA, there will likely be a greater emphasis on innovation to prevent zoonotic diseases combined with biotechnology breakthroughs, which will create a favorable environment for the development of veterinary therapeutics. These methods include systems biology, synthetic biology, and next-generation sequencing among others. Additionally, maintaining investments in multidisciplinary research may accelerate the time to market for new products and enhance the efficiency of therapy development.
The large market potential for veterinary therapeutics is expected to emerge throughout the forecast period as a result of growing economies in emerging markets like Latin America and Asia Pacific. The potential that these markets present are due to a large number of factors, including the increasing cost of living for the urban middle-class population in these regions, which further surges per-capita meat consumption and fuels the need for more effective livestock farming.
Stringent regulations put forward by the USA Food & Drug Administration (FDA) to limit the use of antibiotics for farm animals and the rising cost of innovation-dampening Research and Development investments can hamper the market in the forecast period. If antibiotics are administered to livestock that is raised for food such as swine and other animals, they may lose their efficacy in humans. Antibiotic-resistant bacteria known as superbugs are on the rise as a result of the widespread use of antibiotics in both humans and animals.
The cost of drug innovation has been increasing, as compared to earlier years. The trend is similar for animal healthcare. This is primarily attributed to a limited scope of research for newer diseases in livestock animals. Due to this, drug makers are investing more in the development of innovative drugs for diseases, which are already highly mature. This further raises Research and Development spending and dampens return on investment (ROI). These factors cumulatively propose a negative effect on developmental growth in the swine respiratory diseases treatment market.
Rising Prevalence of Zoonotic Diseases in the USA to Push Growth by 2032
The USA dominates the North American swine respiratory diseases treatment market and held a total share of about 52.9% in 2021. It is expected to continue to experience the same growth rate throughout the forecast period.
Owing to the increased swine respiratory diseases related deaths, high consumption of animal meats, and growing prevalence of zoonotic diseases, producers or manufacturers operating in the market are presented with new growth opportunities to develop unique preventive measures, which would further boost the market in the USA
Surging Need for H1N1 Influenza Treatment in Canada to Drive the Industry Forward
Canada held approximately 47.1% of the share in the North American swine respiratory diseases treatment market in 2021 and it is expected to showcase growth at a lucrative CAGR of 6.7% during the forecast period.
Influenza viruses are frequently found in pigs, who can be infected by humans, birds, or other pigs. Predominant influenza subtypes prevalent in pigs in Canada are H1N1, H1N2, and h4N2. Swine influenza viruses do not generally infect humans; however, these viruses have occasionally infected humans.
Cases mainly emerge because of direct or indirect contact with pigs in numerous settings such as farms or agricultural fairs. The Canadian Food Inspection Agency (CFIA) advises veterinarians and producers to maintain strict biosecurity measures to reduce any hazards to human or animal health.
Rising Cases of Swine Fever in Pigs to Propel Growth in Germany by 2032
Germany is set to exhibit a CAGR of nearly 5.8% in the Europe swine respiratory diseases treatment market during the forecast period. Germany is becoming increasingly popular when it comes to health and innovation. With the surging prevalence of influenza A (H1), as well as increasing surveillance and management measures of the disease implemented by the World Health Organization (WHO), the demand for swine respiratory disease treatment options will grow at a rapid pace.
Mycoplasma-based Swine Diseases to Exhibit High Growth in the Upcoming Decade
Mycoplasma-based causative agents are expected to witness high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 35.2% in 2021. The major pathogen of enzootic pneumonia, a chronic respiratory disease in pigs, is mycoplasma hyopneumoniae. Infections caused by mycoplasma hyopneumoniae are common in practically all swine production locations, which leads to huge economic losses due to increased medicine consumption and lower pig performance.
Common Swine Diseases Are Expected to Be Treated with Antibiotics
The drugs segment is expected to create high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 63.8% in 2021. Antibiotic use during all stages of growth enhances the efficiency and efficacy of body weight gain, lowers death rates & comorbidities, reduces subclinical disease, and improves pig health.
Veterans Prefer Oral Route of Administration to Treat Swine Fever Disease
The oral route of administration is expected to exhibit high growth at a CAGR of 6.3% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 86.3% in 2021. The oral route of administration is the most common form of medication administration in farm animals. Medications are mixed with animal feed for ease of ingestion, which would push the segment.
Veterinary Hospitals to Offer Advanced Treatment Options for Swine Bacterial Diseases
Veterinary hospitals held the highest swine respiratory diseases treatment market share of 37.0% in 2021. Pigs are considered to be better medical research subjects than mice as their size, physiology, and genetic makeup are more similar to humans.
With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.
Some of the recent developments in the swine respiratory diseases treatment market are given below:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | USD 1,978.1 Million |
| Projected Market Valuation (2032) | USD 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | Value (USD Million) |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa |
| Key Market Segments Covered | Causative Agent, Treatment, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Zoetis; Bayer AG; Boehringer Ingelheim GmbH; Elanco Animal Health (Sub. Eli Lilly); Virbac; Norbrook; Ceva Santé Animale; Intervet Inc., (Sub. Merck & Co. Inc.); Vetoquinol SA; Bimeda Inc.; Kyoritsu Seiyaku Corporation; HIPRA; Agrilabs, Inc.; Ashish LifeSciences Ltd.; Cipla Pharmaceuticals.; Thermo Fisher Scientific Inc.; Huvepharma |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Table 01: Global Market Size (US$ Million) Analysis and Forecast 2022 to 2032, by Causative Agent
Table 02: Global Market Size (US$ Million) Analysis and Forecast 2022 to 2032, by Treatment
Table 03: Global Market Size (US$ Million) Analysis and Forecast 2022 to 2032, by Route of Administration
Table 04: Global Market Value (US$ Million) Analysis and Forecast 2022 to 2032, by Distribution Channel
Table 05: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 06: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 07: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 08: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 09: North America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 10: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 11: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 12: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 13: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 14: Latin America Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 15: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 16: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 17: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 18: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 19: Europe Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 20: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 21: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 22: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 23: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 24: South Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 25: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 26: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 27: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 28: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 29: East Asia Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 30: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 31: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 32: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 33: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 34: Oceania Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Table 35: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 36: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Causative Agent
Table 37: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Treatment
Table 38: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration
Table 39: Middle East & Africa Market Size Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Figure 01: Global Market Value Analysis (US$ Million), 2012 to 2021
Figure 02: Global Market Value Forecast (US$ Million), 2022 to 2032
Figure 03: Global Market Absolute $ Opportunity, 2022 to 2032
Figure 04: Global Market Share Analysis (%), by Causative Agent, 2022 to 2032
Figure 05: Global Market Y-o-Y Analysis (%), by Causative Agent, 2022 to 2032
Figure 06: Global Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 07: Global Market Share Analysis (%), by Treatment, 2022 to 2032
Figure 08: Global Market Y-o-Y Analysis (%), by Treatment, 2022 to 2032
Figure 09: Global Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 10: Global Market Share Analysis (%), by Route of Administration, 2022 to 2032
Figure 11: Global Market Y-o-Y Analysis (%), by Route of Administration, 2022 to 2032
Figure 12: Global Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 13: Global Market Share Analysis (%), by Distribution Channel, 2022 to 2032
Figure 14: Global Market Y-o-Y Analysis (%), by Distribution Channel, 2022 to 2032
Figure 15: Global Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 16: North America Market Value Share by Causative Agent 2022 (E)
Figure 17: North America Market Value Share by Treatment 2022 (E)
Figure 18: North America Market Value Share by Route of Administration 2022 (E)
Figure 19: North America Market Value Share by Distribution Channel 2022 (E)
Figure 20: North America Market Value Share by Country 2022 (E)
Figure 21: North America Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 22: North America Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 23: North America Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 24: North America Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 25: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 26: North America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 27: North America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 28: USA Market Value Proportion Analysis, 2021
Figure 29: USA Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 30: USA Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 31: USA Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 32: USA Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 33: Canada Market Value Proportion Analysis, 2021
Figure 34: Canada Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 35: Canada Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 36: Canada Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 37: Canada Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 38: Latin America Market Value Share by Causative Agent 2022 (E)
Figure 39: Latin America Market Value Share by Treatment 2022 (E)
Figure 40: Latin America Market Value Share by Route of Administration 2022 (E)
Figure 41: Latin America Market Value Share by Distribution Channel 2022 (E)
Figure 42: Latin America Market Value Share by Country 2022 (E)
Figure 43: Latin America Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 44: Latin America Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 45: Latin America Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 46: Latin America Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 47: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 49: Latin America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 50: Brazil Market Value Proportion Analysis, 2021
Figure 51: Brazil Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 52: Brazil Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 53: Brazil Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 54: Brazil Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 55: Mexico Market Value Proportion Analysis, 2021
Figure 56: Mexico Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 57: Mexico Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 58: Mexico Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 59: Mexico Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 60: Argentina Market Value Proportion Analysis, 2021
Figure 61: Argentina Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 62: Argentina Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 63: Argentina Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 64: Argentina Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 65: Europe Market Value Share by Causative Agent 2022 (E)
Figure 66: Europe Market Value Share by Treatment 2022 (E)
Figure 67: Europe Market Value Share by Route of Administration 2022 (E)
Figure 68: Europe Market Value Share by Distribution Channel 2022 (E)
Figure 69: Europe Market Value Share by Country 2022 (E)
Figure 70: Europe Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 71: Europe Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 72: Europe Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 73: Europe Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 74: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 75: Europe Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 76: Europe Market Attractiveness Analysis by Country, 2022 to 2032
Figure 77: Italy Market Value Proportion Analysis, 2021
Figure 78: Italy Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 79: Italy Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 80: Italy Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 81: Italy Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 82: Germany Market Value Proportion Analysis, 2021
Figure 83: Germany Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 84: Germany Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 85: Germany Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 86: Germany Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 87: U.K. Market Value Proportion Analysis, 2021
Figure 88: U.K. Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 89: U.K. Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 90: U.K. Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 91: U.K. Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 92: France Market Value Proportion Analysis, 2021
Figure 93: France Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 94: France Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 95: France Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 96: France Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 97: Spain Market Value Proportion Analysis, 2021
Figure 98: Spain Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 99: Spain Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 100: Spain Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 101: Spain Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 102: BENELUX Market Value Proportion Analysis, 2021
Figure 103: BENELUX Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 104: BENELUX Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 105: BENELUX Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 106: BENELUX Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 107: Nordic Countries Market Value Proportion Analysis, 2021
Figure 108: Nordic Countries Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 109: Nordic Countries Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 110: Nordic Countries Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 111: Nordic Countries Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 112: Russia Market Value Proportion Analysis, 2021
Figure 113: Russia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 114: Russia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 115: Russia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 116: Russia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 117: South Asia Market Value Share by Causative Agent 2022 (E)
Figure 118: South Asia Market Value Share by Treatment 2022 (E)
Figure 119: South Asia Market Value Share by Route of Administration 2022 (E)
Figure 120: South Asia Market Value Share by Distribution Channel 2022 (E)
Figure 121: South Asia Market Value Share by Country 2022 (E)
Figure 122: South Asia Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 123: South Asia Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 124: South Asia Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 125: South Asia Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 126: South Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 127: South Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 128: South Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 129: India Market Value Proportion Analysis, 2021
Figure 130: India Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 131: India Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 132: India Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 133: India Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 134: Thailand Market Value Proportion Analysis, 2021
Figure 135: Thailand Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 136: Thailand Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 137: Thailand Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 138: Thailand Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 139: Indonesia Market Value Proportion Analysis, 2021
Figure 140: Indonesia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 141: Indonesia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 142: Indonesia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 143: Indonesia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 144: Malaysia Market Value Proportion Analysis, 2021
Figure 145: Malaysia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 146: Malaysia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 147: Malaysia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 148: Malaysia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 149: East Asia Market Value Share by Causative Agent 2022 (E)
Figure 150: East Asia Market Value Share by Treatment 2022 (E)
Figure 151: East Asia Market Value Share by Route of Administration 2022 (E)
Figure 152: East Asia Market Value Share by Distribution Channel 2022 (E)
Figure 153: East Asia Market Value Share by Country 2022 (E)
Figure 154: East Asia Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 155: East Asia Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 156: East Asia Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 157: East Asia Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 158: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 159: East Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 160: East Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 161: China Market Value Proportion Analysis, 2021
Figure 162: China Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 163: China Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 164: China Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 165: China Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 166: Japan Market Value Proportion Analysis, 2021
Figure 167: Japan Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 168: Japan Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 169: Japan Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 170: Japan Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 171: South Korea Market Value Proportion Analysis, 2021
Figure 172: South Korea Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 173: South Korea Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 174: South Korea Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 175: South Korea Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 176: Oceania Market Value Share by Causative Agent 2022 (E)
Figure 177: Oceania Market Value Share by Treatment 2022 (E)
Figure 178: Oceania Market Value Share by Route of Administration 2022 (E)
Figure 179: Oceania Market Value Share by Distribution Channel 2022 (E)
Figure 180: Oceania Market Value Share by Country 2022 (E)
Figure 181: Oceania Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 182: Oceania Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 183: Oceania Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 184: Oceania Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 185: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 186: Oceania Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 187: Oceania Market Attractiveness Analysis by Country, 2022 to 2032
Figure 188: Australia Market Value Proportion Analysis, 2021
Figure 189: Australia Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 190: Australia Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 191: Australia Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 192: Australia Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 193: New Zealand Market Value Proportion Analysis, 2021
Figure 194: New Zealand Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 195: New Zealand Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 196: New Zealand Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 197: New Zealand Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 198: Middle East & Africa Market Value Share by Causative Agent 2022 (E)
Figure 199: Middle East & Africa Market Value Share by Treatment 2022 (E)
Figure 200: Middle East & Africa Market Value Share by Route of Administration 2022 (E)
Figure 201: Middle East & Africa Market Value Share by Distribution Channel 2022 (E)
Figure 202: Middle East & Africa Market Value Share by Country 2022 (E)
Figure 203: Middle East & Africa Market Historical Market Size (US$ Million) Analysis, 2012 to 2021
Figure 204: Middle East & Africa Market Current and Future Market Size (US$ Million), 2022 to 2032 & Y-o-Y Growth Trend Analysis
Figure 205: Middle East & Africa Market Attractiveness Analysis by Causative Agent, 2022 to 2032
Figure 206: Middle East & Africa Market Attractiveness Analysis by Treatment, 2022 to 2032
Figure 207: Middle East & Africa Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 208: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 209: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032
Figure 210: GCC Countries Market Value Proportion Analysis, 2021
Figure 211: GCC Countries Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 212: GCC Countries Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 213: GCC Countries Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 214: GCC Countries Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 215: South Africa Market Value Proportion Analysis, 2021
Figure 216: South Africa Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 217: South Africa Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 218: South Africa Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 219: South Africa Market Share Analysis (%), by Distribution Channel, 2021 to 2032
Figure 220: North Africa Market Value Proportion Analysis, 2021
Figure 221: North Africa Market Share Analysis (%), by Causative Agent, 2021 to 2032
Figure 222: North Africa Market Share Analysis (%), by Treatment, 2021 to 2032
Figure 223: North Africa Market Share Analysis (%), by Route of Administration, 2021 to 2032
Figure 224: North Africa Market Share Analysis (%), by Distribution Channel, 2021 to 2032
The global swine respiratory diseases treatment market was worth USD 1,852.0 Million in 2021 and is set to expand 1.8x over the next ten years.
The swine respiratory diseases treatment market is expected to reach USD 3,649.5 Million by the end of 2032, with sales revenue set to register a 6.3% CAGR.
Emergence of biologics & specialty care, growing awareness & affordability of therapeutics for livestock, and shifting distribution of drugs from traditional channels are some of the key trends in the swine respiratory diseases treatment market.
The USA, Canada, China, the Philippines, and South Korea are expected to drive demand in the swine respiratory diseases treatment market.
North America is one of the key regions, with the USA accounting for about 52.9% of the region’s swine respiratory diseases treatment market in the year 2021.
The swine respiratory disease treatment market in Japan is expected to register growth at a CAGR of 5.2% over the next ten years.
The swine respiratory disease treatment market in Germany is expected to register growth at a CAGR of 5.8% over the next ten years.
China, the USA, and the Philippines are the key producers of swine respiratory diseases treatment
Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc. (Sub. Merck & Co. Inc.), Vetoquinol SA, Bimeda, Inc., Kyoritsu Seiyaku Corporation, HIPRA, Agrilabs, Inc., Ashish LifeSciences Ltd., Cipla Pharmaceuticals., Thermo Fisher Scientific Inc., and Huvepharma, are some of the key players in the swine respiratory diseases treatment market.
The global swine respiratory disease treatment market in South Korea is expected to register growth at a CAGR of 6.1% over the next ten years.
Explore Similar Insights
Swine Respiratory Diseases Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
